SCHEMBL5124739

SCHEMBL5124739

CCc1cccc(CNC[C@@H](OC(=O)CCCc2nc3ccccc3s2)[C@@H](N)Cc2cc(F)cc(F)c2)c1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.44
HPGD P15428 4/20 0.44
HTT P42858 3/20 0.44
POLB P06746 1/20 0.42
ATM Q13315 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
LMNA P02545 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
NPC1 O15118 1/20 0.39
MAPT P10636 1/20 0.39
RECQL P46063 1/20 0.39
RAB9A P51151 1/20 0.39
ALOX15 P16050 1/20 0.39
BACE1 P56817 4/20 0.39
CTSB P07858 3/20 0.39
CTSD P07339 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5124749 1.00 ALDH1A1 (0.44) ALDH1A1HPGDHTTPOLBATM
SCHEMBL5579760 0.83 BACE1 (0.38) BACE1CTSBCTSD
SCHEMBL5579766 0.83 BACE1 (0.38) BACE1CTSBCTSD
SCHEMBL4392854 0.82 BACE1 (0.50) ALDH1A1HPGDHTTPOLBATM
SCHEMBL4389304 0.82 BACE1 (0.50) ALDH1A1HPGDHTTPOLBATM
SCHEMBL5124411 0.79 KMT2A (0.42) KMT2ABACE1CTSBCTSD
SCHEMBL5124419 0.79 KMT2A (0.42) KMT2ABACE1CTSBCTSD
SCHEMBL5124858 0.78 BACE1 (0.45) BACE1CTSBCTSD
SCHEMBL5124854 0.78 BACE1 (0.45) BACE1CTSBCTSD
SCHEMBL5580030 0.78 MAPT (0.41) ALDH1A1HTTPOLBLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7294642-B2 1,3-Diamino-2-hydroxypropane pro-drug derivatives ELAN PHARMACEUTICALS, INC. (US) 2007-11-13 US claimed
US-20080161325-A1 e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome ELAN PHARMACEUTICALS, INC. 2008-07-03 US disclosed
US-7294642-B2 1,3-Diamino-2-hydroxypropane pro-drug derivatives ELAN PHARMACEUTICALS, INC. (US) 2007-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161325-A1 e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome BACE1, APP, BACE2 ALDH1A1 2178/4885HPGD 1263/4885HTT 57/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.